PHAXIAM Therapeutics Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Thibaut Fayet

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.09%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Thibaut Fayet (56 yo)

less than a year

Amtszeit

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eric Soyer	Deputy CEO	8.8yrs	€379.72k	0.010% € 1.3k
Jérôme Bailly	Deputy CEO	4.4yrs	€247.91k	0.0062% € 792.3
Thibaut Fayet	Chief Executive Officer	less than a year	keine Daten	0.090% € 11.5k
Céline Breda	Chief Technology Officer	less than a year	keine Daten	keine Daten
Cindy Fevre	Chief Scientific Officer	1.4yrs	keine Daten	keine Daten
Naomi Eichenbaum	Director Investor Relations	no data	keine Daten	keine Daten
Anne-Cécile Fumey	Vice President of Human Resources	8.3yrs	keine Daten	0.0014% € 180.3
Karine Charton	Chief Business Officer	less than a year	keine Daten	0.00066% € 83.8
Pascal Birman	Chief Medical Officer	less than a year	keine Daten	keine Daten
Frederique Vieville	Chief Regulatory Officer	less than a year	keine Daten	keine Daten
Philip Lorenzi	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten
Eric Raymond	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten

1.0yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: 0QSSDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philip Lorenzi	Consultant & Member of Scientific Board	14.4yrs	keine Daten	keine Daten
Eric Raymond	Consultant & Member of Scientific Board	14.7yrs	keine Daten	keine Daten
Bridget Bax	Consultant & Member of Scientific Board	12.4yrs	keine Daten	keine Daten
Arthur Frankel	Consultant & Member of Scientific Board	12.4yrs	keine Daten	keine Daten
Kurt Gunter	Consultant & Member of Scientific Board	12.4yrs	keine Daten	keine Daten
Guy Rigaud	Board Censor	no data	keine Daten	0.12% € 15.8k
Philippe Archinard	Independent Director	11.1yrs	€66.00k	0.017% € 2.2k
Gil Beyen	Vice Chairman	11.1yrs	€572.43k	0.0080% € 1.0k
Hilde Windels	Independent Director	9.8yrs	€51.00k	0.000020% € 2.5
Didier Hoch	Chairman of the Board	less than a year	keine Daten	keine Daten
Leila Nicolas	Representative Director	1.4yrs	keine Daten	keine Daten
Robert Sebbag	Independent Director	less than a year	keine Daten	keine Daten

11.1yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: 0QSSDie Vorstandsmitglieder sind sehr erfahren ( 11.1 ).

PHAXIAM Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter